U.K.-based CRO Sygnature Discovery unveiled plans to expand the footprint of its campus with the addition of a new facility.
Sygnature, which provides integrated drug discovery and preclinical services, said the expansion will double its drug metabolism and pharmacokinetics (DMPK) department as part of the firm’s efforts to bolster its recruitment program.
The department is focused on the delivery and interpretation of discovery DMPK data to pharma and biotech organizations. The new facility will be located at the company’s Alderly Park campus.
“The demand for our DMPK services and expertise is growing rapidly year on year, so we are expanding the team and bringing in more expertise to meet this growing client need,” Dr. Jonathan Williams, Sygnature’s COO, said in a statement.
As part of the expansion, some DMPK employees will be relocating from Nottingham to Alderly Park.
The DMPK department was launched in 2015 with the appointment of Dr. Tim Schulz-Utermoehl as director. Previously, he worked for Shire.